• Clearmind Medicine received a newly granted U.S. patent for “Binge Behavior Regulators,” U.S. Patent No. 12,357,590.
• The patent expands protection around MEAI (5-methoxy-2-aminoindane) and related 2-aminoindan derivatives targeting binge behaviors.
• The grant builds on an earlier U.S. patent, No. 12,350,242, strengthening the company’s U.S. intellectual property position.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Clearmind Medicine Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606290755PRIMZONEFULLFEED9753988) on June 29, 2026, and is solely responsible for the information contained therein.